Jefferies Financial Group Inc. Grows Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• Jefferies Financial Group Inc. increased its stake in IQVIA Holdings Inc. by 93.9% during the first quarter, acquiring an additional 47,382 shares, bringing its total ownership to approximately 97,858 shares valued at $17.25 million.
• Several institutional investors, including the Canada Pension Plan Investment Board and Invesco Ltd., significantly raised their positions in IQVIA during the fourth quarter, contributing to 89.62% of the company's stock being owned by institutional investors.
• IQVIA's recent quarterly earnings report showed a revenue of $4.02 billion, surpassing analyst expectations and marking a 5.3% year-over-year increase, alongside an EPS of $2.81 against a consensus estimate of $2.77.

Jefferies Financial Group Inc. lifted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 93.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 97,858 shares of the medical research company's stock after acquiring an additional 47,382 shares during the quarter. Jefferies Financial Group Inc. owned 0.06% of IQVIA worth $17,252,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. American National Bank & Trust bought a new stake in IQVIA during the 1st quarter valued at about $26,000. Golden State Wealth Management LLC raised its holdings in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new stake in shares of IQVIA in the 1st quarter valued at about $33,000. ST Germain D J Co. Inc. raised its holdings in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares in the last quarter. Finally, GKV Capital Management Co. Inc. bought a new stake in shares of IQVIA in the 4th quarter valued at about $39,000. Institutional investors own 89.62% of the company's stock.

Insider Activity

In other news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

IQVIA Price Performance

Shares of NYSE IQV traded up $0.52 during trading on Monday, hitting $182.97. 1,100,383 shares of the company were exchanged, compared to its average volume of 2,028,470. The company has a market cap of $31.10 billion, a price-to-earnings ratio of 26.48, a PEG ratio of 2.00 and a beta of 1.30. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The firm's fifty day moving average price is $162.11 and its 200 day moving average price is $169.70. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period in the previous year, the firm earned $2.64 EPS. The business's revenue was up 5.3% on a year-over-year basis. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on IQV. Evercore ISI boosted their price target on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a report on Wednesday, July 9th. Barclays lifted their price objective on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Truist Financial boosted their target price on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Cowen restated a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, Mizuho set a $225.00 price objective on shares of IQVIA and gave the company an "outperform" rating in a report on Friday, July 25th. Seven equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $228.62.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.